MIRA earnings analysis
What we found in MIRA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
MIRA continued to report zero revenue for the quarter ended June 30, 2026 and a diluted EPS loss of -$0.03, with no quantitative guidance provided. The principal new development is a Nasdaq minimum-bid deficiency: the stock was below $1.00 for 30 consecutive business days, with compliance required by January 25, 2027. Potential delisting and associated financing and liquidity consequences materially worsen the risk profile.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Remains at Zero
- The company reported zero revenue for the quarter ended June 30, 2026, with diluted EPS of -$0.03, unchanged from the prior quarter and improved from -$0.09 in the year-ago quarter.
- Controls Remained Effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026, and reported no changes in internal control over financial reporting that materially affected, or were reasonably likely to materially affect, controls during the second quarter of 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Nasdaq Minimum-Bid Deficiency
- On July 27, 2026, Nasdaq notified the company that its common stock had remained below the $1.00 minimum closing bid price for 30 consecutive business days. The company has until January 25, 2027, to regain compliance, requiring a closing bid price of at least $1.00 for 10 consecutive business days.
- Potential Nasdaq Delisting
- If compliance is not restored within the initial 180-calendar-day period ending January 25, 2027, the company may need to pursue an additional 180-calendar-day compliance period and potentially effect a reverse stock split; Nasdaq may ultimately delist the securities.
- Intellectual Property Defense Costs
- The filing states that the company anticipates expending significant financial and managerial resources to defend its intellectual property rights and against third-party infringement claims, creating a potential drain on resources while revenue remains zero.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.03
What they said about what is next.
No quantitative revenue or EPS guidance was provided in the filing; forward outlook remains deferred.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 14, 2026
- MIRA Pharmaceuticals, Inc. reported no revenue for the quarter ended March 31, 2026, accompanied by a net loss of $1.15 million, an improvement from a net loss of $1.78 million in the same quarter of the previous year.…
- 10-K · March 31, 2026
- MIRA is a clinical‑stage biotech advancing three oral programs (Ketamir‑2, MIRA‑55, SKNY‑1). The company completed dosing in a randomized Phase 1 (SAD and MAD) study with a total of 56 participants and reports no…
- 10-Q · August 13, 2024
- MIRA reported zero revenue and a widening net loss in Q2 2024: net loss of $1,691,325 (EPS $(0.11)) for the quarter and $(3,409,096) (EPS $(0.23)) for the six months. Cash declined to $2,823,781 at June 30, 2024 (down…
- 10-Q · May 13, 2024
- MIRA reported a net loss of $1,717,771 (loss per share $0.12) for Q1 ended March 31, 2024, with zero revenue. Cash declined to $3,528,695 at quarter-end after using $1,049,536 in operating cash flow. Management…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing MIRA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever